Clinical Trial Update: A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and ocular hypotensive effect of AR-12286 in patients with elevated intraocular pressure, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• AR-12286

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Ocular Hypertension, Open-angle Glaucoma | Phase 2 | Status: COMPLETED